TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RAAS, Inflammation, and Post-operative AF
Brief Summary: Atrial fibrillation (AF) is the most prevalent, sustained type of irregular heartbeat and affects over 2 million Americans. Post-operative AF, which leads to significant morbidity and a prolonged hospital stay, complicates 20% to 40% of cardiopulmonary bypass (CPB) surgical procedures. While recent studies indicate that interruption of the renin-angiotensin-aldosterone system by either angiotensin-converting enzyme (ACE) inhibition or AT1 receptor antagonism decreases the incidence of AF following a heart attack or cardioversion (electric shock to the heart), its effect on the incidence of post-operative AF has not been throughly studied. Studies in both animals and humans suggest that inflammation-induced atrial remodeling plays an important role in the cause of AF. Recent studies also provide evidence that activation of the renin-angiotensin-aldosterone system induces inflammation, myocyte injury, proarrhythmic electrical remodeling, and fibrosis through aldosterone.


Options:
A: Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
B: Arm Label: Metoprolol; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol | Arm Label: Placebo for Metoprolol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Candesartan; Type: EXPERIMENTAL; Interventions: Drug: Candesartan | Arm Label: Placebo for Candesartan; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol; Assigned to Arm(s): Metoprolol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for Metoprolol | Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): Candesartan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for Candesartan
C: Arm Label: Losartan 100mg; Type: EXPERIMENTAL; Interventions: Drug: Losartan 100mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Losartan 100mg; Assigned to Arm(s): Losartan 100mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ramipril; Type: EXPERIMENTAL; Interventions: Drug: Ramipril | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open Label, Single, and Multiple Dose Study of the Safety and Pharmacokinetics of 2 Dose Levels of Pantoprazole Sodium in Children Aged 1 Through 11 Years With Endoscopically Proven GERD
Brief Summary: The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD.


Options:
A: Intervention Type: DRUG; Name: pantoprazole for approximately 9 weeks.; Assigned to Arm(s): N/A
B: Arm Label: Low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Arm Label: High dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid suspension; Assigned to Arm(s): High dose, Low dose
C: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
D: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open Label, Single, and Multiple Dose Study of the Safety and Pharmacokinetics of 2 Dose Levels of Pantoprazole Sodium in Children Aged 1 Through 11 Years With Endoscopically Proven GERD
Brief Summary: The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD.


Options:
A: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
B: Arm Label: Lansoprazole QD; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole microgranules suspension | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lansoprazole microgranules suspension; Assigned to Arm(s): Lansoprazole QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
C: Intervention Type: DRUG; Name: pantoprazole for approximately 9 weeks.; Assigned to Arm(s): N/A
D: Arm Label: Dexlansoprazole MR 30 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 30 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Intrauterine Fetal Death
Brief Summary: Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance to effect the medical termination of pregnancy in the second trimester, either alone or after pretreatment with mifepristone. The primary reasons for this prompt incorporation into standard practice include its low cost and the lack of stringent storage requirements.

Vaginal administration seems to be more efficacious than when given orally. The use of sublingual misoprostol for first trimester abortions has been extensively investigated as evidenced by the large number of publications comparing sublingual to other routes of misoprostol for first trimester pregnancy termination, on the assumption that the sublingual route would have a similar efficacy of the vaginal route. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the second trimester termination following intrauterine fetal death. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.


Options:
A: Arm Label: sublingual misoprostol; Type: EXPERIMENTAL; Interventions: Drug: sublingual misoprostol | Arm Label: vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: vaginal misoprostol | Intervention Type: DRUG; Name: sublingual misoprostol; Assigned to Arm(s): sublingual misoprostol | Intervention Type: DRUG; Name: vaginal misoprostol; Assigned to Arm(s): vaginal misoprostol
B: Arm Label: Misoprostol group; Type: OTHER; Interventions: Drug: Misoprostol | Arm Label: Expectant group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol group
C: Arm Label: Arm A : Operative hysteroscopy; Type: EXPERIMENTAL; Interventions: Procedure: Hysteroscopy | Arm Label: Arm B : Aspirative curettage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Curettage | Intervention Type: PROCEDURE; Name: Hysteroscopy; Assigned to Arm(s): Arm A : Operative hysteroscopy | Intervention Type: PROCEDURE; Name: Curettage; Assigned to Arm(s): Arm B : Aspirative curettage
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Promotion in the Workplace Using Personally Controlled Health Records
Brief Summary: The purpose of this study is to determine whether personally controlled electronic health records can be used for health promotion in a workplace setting.


Options:
A: Intervention Type: DEVICE; Name: Electronic health record and messaging system; Assigned to Arm(s): N/A
B: Arm Label: Diabetes Medication Choice decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Medication Choice decision aid | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice decision aid | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Intervention Type: BEHAVIORAL; Name: Re-Mission; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: 6 months readmission rate to hospital; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Cost-effectiveness of Malaria Prevention in Pregnancy in an Area of Low and Unstable Transmission in Kabale, Uganda: Use of Intermittent Preventive Treatment and Insecticide-treated Nets.
Brief Summary: The purpose of this study is to compare the efficacy and cost-effectiveness of three alternative strategies for the prevention of malaria during pregnancy in an epidemic-prone area of low transmission in the East African Highlands.

The strategies being compared are:

* intermittent preventive treatment with sulfadoxine-pyrimethamine (IPT-SP)
* an insecticide treated net (ITN), and
* intermittent preventive treatment with SP plus an ITN

In addition to the main individually-randomised trial, outcome data was subsequently also gathered on pregnant women whose houses where sprayed with indoor residual insecticides (IRS) as part of a non-randomised district-wide control programme to compare the impact of IRS with the three intervention arms.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine treatment twice during pregnancy | Arm Label: Monthly SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine at 4-week intervals | Arm Label: AZI-SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine treatment twice during pregnancy; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine at 4-week intervals; Assigned to Arm(s): Monthly SP | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice; Assigned to Arm(s): AZI-SP
B: Intervention Type: DRUG; Name: Monthly sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 2-dose sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Insecticide-treated mosquito bed net | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine, Device: Insecticide-treated mosquito bed net | Intervention Type: DRUG; Name: Intermittent preventive treatment:sulphadoxine-pyrimethamine; Assigned to Arm(s): 1, 3 | Intervention Type: DEVICE; Name: Insecticide-treated mosquito bed net; Assigned to Arm(s): 2, 3
D: Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine, amodiaquine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent Preventive Treatment in Schools: a Randomised Controlled Trial of the Impact of IPT on Malaria, Anaemia and Education Amongst Schoolchildren in Western Kenya
Brief Summary: This study seeks to establish whether intermittent preventive treatment (IPT) can reduce malaria among school-going children and its consequent impact on school performance.


Options:
A: Intervention Type: DRUG; Name: Intrarectal quinine; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: sulfadoxine /pyrimethamine plus amodiaquine; Assigned to Arm(s): N/A
D: Arm Label: Combination of Amodiaquine +sulfadoxine-pyrimethamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine + sulfadoxine-pyrimethamine | Arm Label: Dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Sulfadoxine-pyrimethamine alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): Sulfadoxine-pyrimethamine alone | Intervention Type: DRUG; Name: amodiaquine + sulfadoxine-pyrimethamine; Assigned to Arm(s): Combination of Amodiaquine +sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): Dihydroartemisinin-piperaquine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent Preventive Treatment in Schools: a Randomised Controlled Trial of the Impact of IPT on Malaria, Anaemia and Education Amongst Schoolchildren in Western Kenya
Brief Summary: This study seeks to establish whether intermittent preventive treatment (IPT) can reduce malaria among school-going children and its consequent impact on school performance.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sulphadoxine-pyrimethamine; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine, Drug: Sulphadoxine-pryrimethamine | Arm Label: Mefloquine; Type: EXPERIMENTAL; Interventions: Drug: mefloquine, Drug: IPTi mefloquine | Arm Label: Chlorproguanil dapsone; Type: EXPERIMENTAL; Interventions: Drug: Chlorproguanil-dapsone, Drug: Chlorproguanil dapsone | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil-dapsone; Assigned to Arm(s): Chlorproguanil dapsone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sulphadoxine-pryrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: IPTi mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil dapsone; Assigned to Arm(s): Chlorproguanil dapsone
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Sulfadoxine/pyrimethamine and artesunate; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfalene-pyrimethamine plus amodiaquine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin plus piperaquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine pyrimethamine plus piperaquine | Intervention Type: DRUG; Name: sulfalene-pyrimethamine plus amodiaquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dihydroartemisinin plus piperaquine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: sulfadoxine pyrimethamine plus piperaquine; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of bilateral deep brain stimulation of the internal globus pallidus for treating idiopathic generalized or severe segmental dystonia.


Options:
A: Intervention Type: DEVICE; Name: Deep brain stimulation of the internal globus pallidus; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Deep brain stimulation (DBS) | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Deep brain stimulation (DBS) | Intervention Type: DEVICE; Name: Deep brain stimulation (DBS); Assigned to Arm(s): 1, 2
C: Intervention Type: DEVICE; Name: Deep brain stimulation; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Bilateral Deep Brain Stimulation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: best medical therapy | Intervention Type: DEVICE; Name: Bilateral Deep Brain Stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: best medical therapy; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention
Brief Summary: Primary Aim

To determine whether;

* Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment

Secondary Aims

To determine whether;

* Donepezil has a significant positive or negative impact upon quality of life compared with placebo
* whether there is a significant difference between Donepezil and placebo with respect to cognitive performance
* the cost effectiveness of the pharmacological treatment for agitation


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aricept (donepezil SR 23 mg) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aricept (donepezil IR 10 mg) | Intervention Type: DRUG; Name: Aricept (donepezil SR 23 mg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aricept (donepezil IR 10 mg); Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)
Brief Summary: To investigate the superiority of a combination of irinotecan and cisplatin and the non-inferiority of S-1 compared to continuous infusion of 5-FU in advanced gastric cancer


Options:
A: Intervention Type: DRUG; Name: continuous infusion of 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: combination of irinotecan and cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oral administration of S-1; Assigned to Arm(s): N/A
B: Arm Label: EOX; Type: ACTIVE_COMPARATOR; Interventions: Other: EOX | Arm Label: mDCF; Type: ACTIVE_COMPARATOR; Interventions: Other: mDCF | Intervention Type: OTHER; Name: EOX; Assigned to Arm(s): EOX | Intervention Type: OTHER; Name: mDCF; Assigned to Arm(s): mDCF
C: Arm Label: ECX; Type: EXPERIMENTAL; Interventions: Drug: Epirubicin, Drug: Cisplatin, capecitabine | Arm Label: CX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, capecitabine | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ECX | Intervention Type: DRUG; Name: Cisplatin, capecitabine; Assigned to Arm(s): CX, ECX
D: Arm Label: S-1,Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP | Arm Label: Capecitabine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: XP | Intervention Type: DRUG; Name: SP; Assigned to Arm(s): S-1,Cisplatin | Intervention Type: DRUG; Name: XP; Assigned to Arm(s): Capecitabine, Cisplatin

Answer: A